AstraZeneca has announced that its treatment for advanced gastric cancer, Lynparza (olaparib), failed to meet the primary endpoint of overall …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations

